$ELAB

NorthStrive Biosciences, a PMGC Holdings subsidiary (NASDAQ: ELAB), and Yuva Biosciences launched a 6-month Expansion Program to advance 4 AI-discovered compounds for cardiac disease and obesity. The program aims to nominate a lead and backup compound, with updated agreement terms and expanded rights.

PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss Proposed Mice2Space spaceflight study would evaluate EL-22

PMGC Holdings (ELAB) signed a non-binding term sheet with Orbit2Orbit for space-based research, manufacturing, and a CAD $200,000 equity investment. The collaboration includes testing PMGC's drug candidates in microgravity and manufacturing spaceflight hardware. The deal is subject to final agreements and approvals.

PMGC Holdings Inc. (ELAB) terminated its planned acquisition of a 76% stake in a precision machining company after due diligence revealed lower-than-expected financial performance. The company reaffirmed its disciplined M&A strategy and is investing in aerospace & defense manufacturing, robotics, and automation to boost capacity and efficiency. PMGC is evaluating multiple acquisition opportunities and integrating portfolio companies to improve operational efficiency.

PMGC Holdings Inc. (ELAB) announced a 1-for-10 reverse stock split, effective August 21, 2026. The split will reduce outstanding shares to approximately 809,584 from 8,095,835, with the trading symbol remaining ELAB. Shareholder equity value will not be affected, but share prices and outstanding equity awards will adjust proportionally.

PMGC Holdings Inc. (Nasdaq: ELAB) filed its Q2 2026 Form 10-Q for the six months ended June 30, 2026. Total assets rose to about $36.6M, up 184% from year-end 2025 and 290% YoY. Q2 revenue was about $1.31M versus $0 in 2025, with A&B Aerospace contributing after its May 11, 2026 acquisition.

PMGC Holdings’ subsidiary NorthStrive Biosciences said it will start an independent flow cytometry study to quantify myostatin antigen expression on its engineered probiotic EL-22. The results are intended to support comparability with materials made by MOA Life Plus Co. Ltd. Shares rose 14.06% to $1.20, per Benzinga Pro.

PMGC Holdings Inc. (NASDAQ: ELAB) said its subsidiary NorthStrive Biosciences plans an independent FACS flow cytometry study to quantify latent myostatin antigen expression on NorthStrive-manufactured EL-22 (engineered Lactobacillus casei) and compare it with material previously made by MOA Life Plus Co. Ltd. The work aims to support product identity, manufacturing consistency, and IND-enabling characterization.

PMGC Holdings’ NASDAQ-listed ELAB rose more than 37% after an SEC filing said AGA Precision Systems LLC will merge into A&B Aerospace Inc., with A&B as the surviving entity. AGA membership interests will be canceled without consideration, while A&B shares remain unchanged. The filing dated Jul. 2 was signed by CEO Graydon Bensler. ELAB closed at $1.06.

PMGC Holdings Inc. (ELAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001840563 0001840563 2026-07-02 2026-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repor